COVID-19: Merck Claims Experimental Pill Reduces Risk Of Death By 50%

The oral antiviral Molnupiravir is going to be supplied by five Indian pharmaceutical companies who have signed licensing agreements with the parent company

Related Keywords

Taiwan ,Japan ,Philippines ,United States ,United Kingdom ,Argentina ,Brazil ,South Africa ,Colombia ,Guatemala ,Canada ,Russia ,Ukraine ,Mexico ,Germany ,India ,Egypt ,Israel ,Italy ,Sweden ,Chile ,Poland ,France ,Spain ,German ,Bridge Biotherapeutics ,Sun Pharmaceutical Industries ,Emory University ,Drug Administration ,Emcure Pharmaceuticals ,Reddy Laboratories ,Hetero Labs ,Cipla ,Drug Innovations ,Laboratories Limited ,Emcure Pharmaceuticals Limited ,Hetero Labs Limited ,Sun Pharmaceutical Industries Limited ,Merck Covid 19 Drug ,Covid 19 Drug ,Anti Covid Drug ,Olnupiravir ,Hat Is Molnuprivair ,Ill For Covid 19 ,Molnupiravir Covid 19 ,Molnupiravir Merck ,Merck Covid 19 ,Ove Out Trial ,